Patient & Survivor Care
Conference Coverage
T-DXd benefits persist for HER2-low breast cancer
Extended follow-up of DESTINY-Breast04 confirms survival benefit of T-DXd for HER2-low advanced breast cancer.
Latest News
Breaking barriers to colorectal cancer care for Black patients
“Black patients diagnosed with advanced-stage cancers require more intensive, expensive, and time-consuming treatment regimens that can be...
Conference Coverage
How can we improve our approach to cancer-related fatigue?
“Cancer-related fatigue is one of the most underestimated and least researched side effects.”
From the Journals
ADC with radiotherapy for brain mets ups risk of necrosis
“Clinicians should be cognizant of the [symptomatic radiation necrosis] risk and monitor patients closely when treating concurrently with ADCs.”...
Conference Coverage
Omitting surgery may be safe in early BC after neoadjuvant pCR
A small trial in early breast cancer has reported 100% disease-free survival at 3 years in women who skipped surgery following pathologic complete...
Conference Coverage
Neoadjuvant, adjuvant, or both? The debate in NSCLC rages on
The question of whether to give upfront immunochemotherapy in resectable non–small cell lung cancer, wait until after surgery, or give both...
Latest News
Induction chemotherapy in first line improves survival for locally advanced cervical cancer
With similar results reported for pembrolizumab, a question has arisen about how to incorporate induction chemotherapy and pembrolizumab into a...
Conference Coverage
Enfortumab vedotin/pembrolizumab hailed as new standard for upfront mUC
After decades of stagnation, an almost doubling of life expectancy has set a new bar for the first-line treatment of locally advanced/metastatic...
Conference Coverage
The sobering facts about alcohol and cancer
An ESMO session highlights the well-known links between alcohol consumption and cancer and calls on healthcare professionals to do more to raise...
Conference Coverage
Chemo-immunotherapy good, adding a PARP inhibitor better in endometrial cancer?
Dr. Tan noted, the AtTEnd data "continue to validate practice-changing therapy for dMMR endometrial cancer patients."
Conference Coverage
Perioperative nivolumab improves EFS in resectable NSCLC
Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs. neoadjuvant nivolumab plus...